Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib in Advanced NSCLC with EGFR Exon 20 Insertion Mutation
NCT04958967Phase 1Withdrawn
- Sponsor
- Allist Pharmaceuticals
- Start
- Oct 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of furmonertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Allist Pharmaceuticals. Primary endpoint: Overall Response Rate up to 12 months. Planned start Oct 2021; status: withdrawn.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04958967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04958967.